An automated radiopharmaceutical production and quality control system includes a particle accelerator, a radiopharmaceutical micro-synthesis subsystem, and quality control subsystem. The micro-accelerator of the improved biomarker generator is optimized for producing radioisotopes useful in synthesizing radiopharmaceuticals in quantities on the order of multiple unit doses, allowing for significant reductions in size, power requirements, and weight when compared to conventional radiopharmaceutical cyclotrons. The radiopharmaceutical micro-synthesis subsystem encompasses a small volume chemical synthesis system comprising a microreactor and/or a microfluidic chip and optimized for synthesizing the radiopharmaceutical in small quantities, allowing for significant reductions in processing time and in the quantity of radioisotope required. The automated quality control subsystem is used to test the composition and characteristics of the radiopharmaceutical to ensure that it is safe to inject.

Certain embodiments of the present invention relate to a system and a method for producing a radiopharmaceutical, wherein the system is formed from and/or provides a microfluidic flow system. In certain embodiments, the system comprises a radioisotope isolation module, a radiopharmaceutical production module, a purification module and a quality control module.

A device for automated characterization of radioactive analytes that provides an integrated system with liquid handling and plate reading components. The device can be further configured to include a chromatographic subsystem. Also provided is a method of using such a device, providing addition of a radioactive sample and a sequence of operations involving the abovementioned components of the system. The system is configured with radiation shielding in such a way that manipulations of radioactive samples do not interfere with concurrent radioactive measurements.

A method for process monitoring and control of a chemical reactor in which a chemical reaction utilizing a halogenated selectivity modifier is performed includes: measuring a level of halogenated components in an inlet stream of a reactor inlet; measuring a level of halogenated components in an outlet stream of a reactor outlet; based on the level of halogenated components at the inlet stream and the outlet stream, determining a process performance indicator associated with a halogenated component; and adjusting an amount of halogenated selectivity modifier added to the reactor based on the process performance indicator.

The present invention discloses a targeting polypeptide compound having dual targets, comprising a TATE cyclic peptide structure, an RGD cyclic peptide structure and a NOTA chelating group, wherein the TATE cyclic peptide structure, the RGD cyclic peptide structure and the NOTA chelating group are respectively linked by a PEG segment having a polymerization degree of 1 to 5 or directly linked to a same glutamic acid; the structure of the polypeptide compound can be represented as NOTA-PEGn-Glu{PEGm-TATE}-PEGP-RGD, where m, n and p are an integer from 0 to 5 respectively. The present invention further discloses a TATE-RGD dual-target radioactive molecular probe based on the polypeptide compound. The TATE-RGD dual-target polypeptide drug of the present invention may simultaneously bind to SSTR, integrin v3, has higher receptor binding affinity and uptake, more excellent non-target tissue clearance rate, and better in vivo and in vitro stability.

An embodiment of a method for real time material identification is described that comprises determining an approximate mass value for an unknown material from spectral information derived from mass spectral analysis of the unknown material; retrieving profile models that correspond to a known material from a data structure using the approximate mass value; fitting a sample profile for the unknown material from the spectral information to the profile models to generate a fit score for each fit, wherein the lowest fit score corresponds to the best fit; calculating a mass value from the best fitting profile model and the sample profile.

A method for process monitoring and control of a chemical reactor in which a chemical reaction utilizing a halogenated selectivity modifier is performed includes: measuring a level of halogenated components in an inlet stream of a reactor inlet; measuring a level of halogenated components in an outlet stream of a reactor outlet; based on the level of halogenated components at the inlet stream and the outlet stream, determining a process performance indicator associated with a halogenated component; and adjusting an amount of halogenated selectivity modifier added to the reactor based on the process performance indicator.

An embodiment of a method for real time material identification is described that comprises determining an approximate mass value for an unknown material from spectral information derived from mass spectral analysis of the unknown material; retrieving profile models that correspond to a known material from a data structure using the approximate mass value; fitting a sample profile for the unknown material from the spectral information to the profile models to generate a fit score for each fit, wherein the lowest fit score corresponds to the best fit; calculating a mass value from the best fitting profile model and the sample profile.

A device for automated characterization of radioactive analytes that provides an integrated system with liquid handling and plate reading components. The device can be further configured to include a chromatographic subsystem. Also provided is a method of using such a device, providing addition of a radioactive sample and a sequence of operations involving the abovementioned components of the system. The system is configured with radiation shielding in such a way that manipulations of radioactive samples do not interfere with concurrent radioactive measurements.

Certain embodiments of the present invention relate to a system and a method for producing a radiopharmaceutical, wherein the system is formed from and/or provides a microfluidic flow system. In certain embodiments, the system comprises a radioisotope isolation module, a radiopharmaceutical production module, a purification module and a quality control module.